Core Viewpoint - The company expects a loss of 170 million to 255 million yuan in 2025, with a non-recurring loss of 210 million to 315 million yuan, primarily due to increased R&D investments to accelerate its innovation pipeline [1] Group 1: Financial Performance - The company anticipates a significant increase in R&D expenses, projected to reach approximately 1 billion yuan, which is a substantial year-on-year growth and a key factor affecting current profits [1] - The company completed the acquisition of an additional 29% minority stake in its subsidiary, Giant Stone Biotechnology, raising its ownership to 80%, which will increase the impact of Giant Stone's losses on the consolidated financial statements [1] Group 2: R&D Progress - During the reporting period, multiple products in the pipeline made significant progress, with four antibody drugs, six ADC products, and one mRNA vaccine receiving clinical trial approvals for the first time in 2025 [1] - One monoclonal antibody product (Omarizumab injection) received approval for a new indication, while another monoclonal antibody product (Pertuzumab injection) had its listing application accepted; additionally, two ADC products entered Phase III clinical trials [1] Group 3: Business Operations - The company is actively consolidating its competitive position in the functional raw materials business, particularly by increasing sales of caffeine products [1] - However, due to market factors, the gross margin and profitability of caffeine products slightly declined compared to the same period last year, leading to a decrease in profits from the functional raw materials business [1]

Core Viewpoint - The company expects a loss of 170 million to 255 million yuan in 2025, with a non-recurring loss of 210 million to 315 million yuan, primarily due to increased R&D investments to accelerate innovation pipelines [1] R&D Investments - The company is significantly increasing R&D expenditures, projected to reach approximately 1 billion yuan for the year, marking a substantial year-on-year increase [1] - Multiple products in the pipeline have made significant progress, with four antibody drugs, six ADC products, and one mRNA vaccine receiving clinical trial approvals for the first time in 2025 [1] - A monoclonal antibody product (Omalizumab injection) has received approval for a new indication, while another monoclonal antibody product (Pertuzumab injection) has had its listing application accepted [1] - Two ADC products have entered Phase III clinical trials [1] Subsidiary Acquisition - In early November 2025, the company completed the acquisition of an additional 29% minority stake in its subsidiary, Jushi Biotech, increasing its ownership to 80% [1] - Jushi Biotech is currently not profitable due to significant investments in its pipeline, and the increased ownership will amplify its impact on the company's consolidated financial statements [1] Functional Raw Materials Business - The company is actively consolidating its competitive position in the functional raw materials sector, particularly in caffeine products, which have seen increased sales [1] - However, due to market factors, the gross margin and profitability of caffeine products have slightly declined compared to the same period last year, leading to a decrease in profits from the functional raw materials business [1]

新诺威公告，预计2025年度净利润亏损1.7亿元–2.55亿元，上年同期盈利5372.63万元。报告期内，公司 为加速推进创新管线，持续加大研发投入。受上述研发活动推动，全年研发费用增至约10亿元，同比有 较大增长，是影响当期利润的重要因素。 ...

证券之星消息，1月15日化学制药板块较上一交易日下跌1.4%，向日葵领跌。当日上证指数报收于 4112.6，下跌0.33%。深证成指报收于14306.73，上涨0.41%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300452 | 山河药辅 | 16.85 | 20.01% | 41.42万 | | 6.70亿 | | 301075 | 多瑞医药 | 62.71 | 11.48% | 2.65万 | | 1.65 Z | | 688176 | 亚虹医药 | 13.16 | 7.69% | 26.47万 | | 3.45亿 | | 300401 | 化园生物 | 16.52 | 3.57% | 1 50.30万 | | 8.28亿 | | 000739 | 普洛药业 | 18.13 | 3.30% | 27.08万 | | 4.87亿 | | 002923 | 润都股份 | 13.04 | 3.16% | 9.42万 | | 1.23亿 | | ...

Core Viewpoint - The company, XinNuoWei, is forecasting a significant net loss for the fiscal year 2025, projecting a loss between 170 million to 255 million yuan, contrasting with a profit of 53.73 million yuan in the same period last year [2] Group 1: Financial Performance - The expected net loss for 2025 is between 170 million to 255 million yuan, compared to a profit of 53.73 million yuan in the previous year [2] - The company has increased its R&D expenditure to approximately 1 billion yuan for the year, indicating a substantial year-on-year growth in innovation pipeline investments [2] Group 2: Business Operations - The acquisition of minority stakes in Jushi Bio has contributed to the widening of losses for the company [2] - The functional raw materials business has seen a reduction in profits due to a decline in the gross margin of caffeine-related products [2]

Group 1 - The core viewpoint of the article is that Fujilai (301258.SZ) currently does not have any plans for a CRO (Contract Research Organization) business layout [1] Group 2 - The company has communicated this information through an interactive platform [1]

（记者 王瀚黎） 每经AI快讯，康芝药业1月15日晚间发布公告称，公司第七届第二次董事会会议于2026年1月15日在海 口国家高新技术产业开发区药谷工业园药谷三路6号会议室以现场及通讯表决方式召开。会议审议了 《关于调整公司组织架构的议案》等文件。 每经头条（nbdtoutiao）——不到20万元，就能买特斯拉了？"廉价版"Model 3或进入中国市场，续航里 程480公里！关于自动驾驶，美国市场也有大调整 ...

Group 1 - The core point of the news is that Haofan Bio experienced a decline of 5.02% in its stock price, closing at 54.50 yuan per share, with a trading volume of 1.07 billion yuan and a turnover rate of 4.60%, resulting in a total market capitalization of 58.86 billion yuan [1] - Haofan Bio, established on December 2, 2003, and listed on July 12, 2023, is located in Suzhou, Jiangsu Province, and specializes in the research and sales of peptide synthesis reagents, protein crosslinkers, and molecular building blocks [1] - The revenue composition of Haofan Bio's main business includes peptide synthesis reagents at 81.89%, general molecular building blocks at 10.99%, protein reagents at 6.11%, and other products at 1.01% [1] Group 2 - Among the top circulating shareholders of Haofan Bio, a fund under Huatai-PineBridge holds a significant position, with the Huatai-PineBridge Healthcare Mixed Fund (470006) increasing its holdings by 264,300 shares to a total of 866,800 shares, representing 2.06% of the circulating shares [2] - The Huatai-PineBridge Healthcare Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.486 billion yuan, achieving a year-to-date return of 10.53% and a one-year return of 37.91% [2] - The fund manager of Huatai-PineBridge Healthcare Mixed Fund is Zheng Lei, who has a tenure of 11 years and 33 days, with the fund's total asset scale at 8.093 billion yuan [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我 公司致力于医药、大健康和高科技产业投资，未来将打造医药创新、医疗器械和医药服务的大健康产业 集群和TMT方向的高科技产业集群，把握中国经济转型的机遇。公司愿景是"健康承载梦想，行动成就 未来"。 根据申万行业分类（2021），向日葵（维权）属于医药生物-化学制药-化学制剂。 2026年1月14日，公司收到中国证监会下发的《立案告知书》（编号：证监立案字01120260003号），因 公司涉嫌信息披露违法违规被立案调查。 立案后，公司股票的表现如下： 而在中国证券监督管理委员会的官网：发布了标题为《浙江证监局对向日葵重组预案涉嫌误导性陈述立 案调查》：2025年9月22日，浙江向日葵大健康科技股份有限公司（简称向日葵）披露重组预案。近 期，重组标的的实际产能和业务模式引发市场质疑，浙江证监局依法开展核查工作，发现重组预案涉嫌 误导性陈述。 初步判断：20 ...

（文章来源：证券日报） 证券日报网讯 1月14日，盟科药业发布公告称，公司通过国家高新技术企业重新认定，由全国高新技术 企业认定管理工作领导小组办公室核发，可连续三年按15%税率缴纳企业所得税，有助于提升核心竞争 力。 ...